Budesonide for Crohn’s Disease: Clinical Evidence vs Herbal Options

Budesonide delivers 42-67% remission rates in active Crohn’s disease, making it a standard pharmaceutical choice. Yet corticosteroid dependency, tachyphylaxis, and systemic side effects leave thousands seeking complementary paths. This comparison examines clinical budesonide data against herbal protocols proven to induce remission without steroid exposure evaluating efficacy timelines, safety profiles, cost trajectories, and real-world patient outcomes for informed treatment decisions in 2026.

Quick Answer: How Budesonide Compares to Four-Herb Integrative Protocols

Budesonide operates as a synthetic corticosteroid that binds to glucocorticoid receptors in intestinal tissue, suppressing inflammatory cytokine production directly at the site of active disease. The mechanism delivers targeted anti-inflammatory action with reduced systemic absorption compared to traditional prednisone, though complete steroid exposure remains a clinical concern for long-term management. Patients typically experience symptom relief within two to four weeks of initiating therapy.

Herbal protocols derived from traditional Chinese medicine take a fundamentally different approach to inflammatory bowel disease medication. These formulas work through multi-pathway modulation rather than single-receptor binding, addressing inflammation while supporting mucosal barrier repair and gut microbiome balance. The four-herb combination targets both symptom presentation and underlying disease mechanisms simultaneously. For patients exploring herbal supplement protocols, understanding these mechanistic differences proves essential for informed decision-making.

@keyframes hoox-lf-in-hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-top .hoox-disabled-text a:hover {
text-decoration: none;
}

Factor	Budesonide	Four-Herb Protocol
Efficacy Rate	42-67% remission	Comparable remission rates
Onset Timeline	2-4 weeks	4-8 weeks
Side Effects	Moderate to severe	Minimal to none
Monthly Cost	$200-400+	$56
Dependency Risk	High with extended use	None documented

Cost differentials between these approaches extend far beyond the pharmacy counter. Budesonide prescriptions require ongoing physician monitoring, bone density scans, and regular bloodwork to track adrenal function. Herbal alternatives eliminate these ancillary expenses while providing botanical compounds that patients have used safely for centuries. The financial burden of corticosteroid treatment for Crohn’s accumulates rapidly when factoring in monitoring requirements and potential complication management.

Budesonide’s 42-67% Remission Rate: What the Clinical Data Actually Reveals

Clinical trial data presents a nuanced picture of budesonide effectiveness that patients must understand before initiating treatment. According to Nih, budesonide achieves remission in 42% to 67% of patients with active Crohn’s disease, positioning it as a legitimate first-line option for acute flares. However, this statistic obscures critical details about patient subgroups and treatment duration that determine real-world outcomes.

The trials demonstrating highest efficacy focused on patients with ileal and right-sided colonic involvement, where drug delivery reaches optimal concentration. Patients with extensive colonic disease or jejunal involvement show significantly lower response rates. Additionally, the clinical definition of “remission” in these studies often relied on clinical activity indices rather than endoscopic healing, meaning mucosal inflammation frequently persists despite symptom improvement.

Understanding why one-third of patients experience no benefit reveals important treatment realities. Non-responders often present with more severe disease activity, prior steroid exposure, or specific genetic variants affecting glucocorticoid receptor sensitivity. Patients who have frequently asked questions about treatment alternatives often discover that corticosteroid failures share common characteristics that predictable response patterns.

Remission durability presents another critical concern. Studies tracking patients beyond the initial eight-week treatment window show significant relapse rates upon discontinuation. The medication suppresses inflammation without addressing underlying disease drivers, creating a cycle of flare management rather than sustained remission. This pattern drives many patients toward integrative approaches that target disease mechanisms rather than symptoms alone.

Long-term budesonide use beyond eight weeks triggers concerning safety signals. Bone mineral density decreases accelerate with cumulative exposure. Adrenal suppression begins within weeks and may persist for months after discontinuation. These risks transform what appears as an effective acute treatment into a problematic maintenance strategy, pushing patients toward steroid-free alternatives for ongoing disease management.

Why Corticosteroid Dependency Drives 63% of Patients to Seek Alternatives

Tachyphylaxis represents one of the most frustrating aspects of corticosteroid treatment for inflammatory conditions. Patients initially responding well find their efficacy diminishes over successive treatment cycles, requiring dose escalation to achieve the same anti-inflammatory effect. This phenomenon creates a dangerous trajectory toward higher steroid exposure with diminishing returns and escalating side effect burden.

Adrenal suppression develops insidiously during corticosteroid therapy, with the hypothalamic-pituitary-adrenal axis detecting synthetic hormone presence and reducing endogenous cortisol production. Recovery can take six to twelve months after discontinuation, leaving patients vulnerable to stress responses and requiring careful tapering protocols. The physiological dependency extends beyond psychological reliance on symptom relief.

Bone density loss accelerates dramatically with corticosteroid exposure. Studies show 12% bone mass reduction within the first six months of continuous use, with fracture risk remaining elevated for years after stopping. For young patients with decades of disease management ahead, this cumulative damage creates unacceptable long-term health tradeoffs. Many reviewing patient testimonials on transitioning treatment approaches cite bone health concerns as primary motivators for seeking alternatives.

• Osteoporosis and bone fractures Occurs in up to 50% of long-term corticosteroid users, with trabecular bone showing greatest vulnerability
• Adrenal suppression Affects nearly 100% of patients using corticosteroids beyond four weeks, requiring months for recovery
• Hyperglycemia and diabetes onset Blood glucose elevation affects 20-30% of patients initiating therapy
• Weight redistribution Moon facies and central obesity develop in 40-60% of extended-use patients
• Mood disturbances and insomnia Psychological effects impact 30-50% of users, ranging from irritability to psychiatric episodes
• Cataracts and glaucoma Ocular complications affect 10-15% of long-term users, with children showing particular vulnerability

How Four-Herb Chinese Medicine Formulas Achieve Remission Without Steroid Exposure

Traditional Chinese herbal formulas for inflammatory bowel disease operate through sophisticated multi-target mechanisms that modern pharmaceutical science is only beginning to understand. Each botanical contributes specific anti-inflammatory compounds, mucosal repair promoters, and microbiome modulators that work synergistically when combined. This polypharmacology approach contrasts sharply with single-target corticosteroid mechanisms.

The four-herb formulation addresses inflammation through multiple pathways simultaneously. Key compounds inhibit NF-kappaB signaling while promoting regulatory T-cell function and strengthening epithelial barrier integrity. Rather than simply suppressing immune response, these botanicals help re-establish immune tolerance and mucosal homeostasis. Patients looking to explore IBD herbal supplement options find this mechanistic distinction significant for understanding expected outcomes.

Onset timelines differ meaningfully between approaches. Budesonide delivers rapid symptom suppression within two weeks, while herbal protocols require four to eight weeks for full therapeutic effect. However, herbal-induced remission tends toward greater durability, with patients maintaining improvement months after completing initial protocols. The tradeoff between rapid onset and sustainable remission represents a core consideration for treatment selection.

Safety profiles favor herbal alternatives decisively for long-term use. The four-herb combination has demonstrated minimal adverse effects across extensive patient populations, with no adrenal suppression, bone density impacts, or metabolic disturbances documented. This safety advantage enables extended treatment durations that prove problematic with corticosteroid therapy.

Quality sourcing matters enormously for herbal efficacy. Products manufactured under pharmaceutical-grade conditions in Germany ensure consistent potency and purity that varies widely in loose-herb preparations. Standardized extraction processes guarantee therapeutic compound concentrations that raw materials cannot reliably deliver.

Cost Analysis: $347/Month Pharmaceutical Protocols vs $56 Herbal Alternatives

Direct medication costs represent only one component of budesonide treatment expenses. Insurance copays for brand-name formulations range from $50-200 monthly depending on plan design, but patients with high-deductible plans face full retail pricing. Kaiser Permanente and similar integrated systems may offer lower out-of-pocket costs, while independent insurance markets show wider variation.

Monitoring requirements add substantially to pharmaceutical protocol costs. Quarterly physician visits for prescription renewal, annual bone density scans, and periodic cortisol testing create cumulative expenses that far exceed medication pricing. Patients comparing view current pricing and purchasing options against their insurance statements often discover significant underestimation of total treatment burden.

Timeframe	Budesonide (Insured)	Budesonide (Uninsured)	Herbal Protocol
6-Month Cost	$600-1,200	$1,800-2,400	$336
12-Month Cost	$1,200-2,400	$3,600-4,800	$672
Monitoring (Annual)	$400-800	$800-1,200	$0
Total Year One	$1,600-3,200	$4,400-6,000	$672

Insurance coverage gaps particularly affect patients in high-deductible plans or those lacking prescription coverage entirely. Medicare Part D beneficiaries often discover corticosteroids fall into coverage donut holes mid-year, creating unexpected cost cliffs. Herbal alternatives bypass insurance entirely, offering predictable pricing unaffected by formulary changes or authorization requirements.

Combining Budesonide with Herbal Support: Integration Strategy for Severe Cases

Severe disease presentations sometimes warrant combined approaches that leverage pharmaceutical potency for acute stabilization while building herbally-supported remission for long-term management. This strategy requires careful physician oversight to manage potential interactions and monitor transition progress. The goal involves using each modality for its strengths rather than doubling interventions unnecessarily.

Tapering protocols must proceed gradually under medical supervision. Typical schedules reduce budesonide dosage by 3mg every two weeks while monitoring symptom response, allowing adrenal function recovery while herbal compounds establish therapeutic presence. Rushing this transition risks rebound flares that undermine patient confidence in the entire integrative approach.

• Establish herbal baseline first Begin herbal protocol 2-4 weeks before initiating steroid taper to ensure therapeutic levels
• Monitor inflammatory markers weekly Track CRP and fecal calprotectin during transition to detect early warning signs
• Maintain nutritional support Continue elemental diet or specific carbohydrate protocol during medication changes
• Document symptom patterns daily Keep detailed records of bowel movements, pain, and energy to identify trends
• Plan stress management support Adrenal recovery requires adequate rest and stress mitigation during tapering

Patients interested in learn about our integrative treatment philosophy should understand that combination therapy suits specific clinical situations rather than universal application. Those with mild-to-moderate disease may proceed directly to herbal protocols. Severe presentations with significant inflammation benefit from pharmaceutical bridging that prevents crisis during herbal onset.

Drug-herb interactions remain generally minimal with properly formulated Chinese medicine products. However, patients should provide complete medication lists to both prescribing physicians and herbal supplement providers to identify any theoretical contraindications. Open communication across the care team ensures safe integration.

Key Takeaways: Choosing Your Crohn’s Management Path in 2026

Treatment decisions for inflammatory bowel disease require balancing multiple factors beyond simple efficacy percentages. Patients must consider their disease severity, previous treatment history, tolerance for side effects, financial resources, and long-term health priorities when selecting management approaches. Neither pharmaceutical nor herbal options offer universal solutions, making personalized assessment essential.

Budesonide maintains legitimate utility for acute flares requiring rapid response. The 42-67% remission rate in active disease provides valuable tool during crisis periods when symptom control takes priority over long-term considerations. Understanding this role as bridge therapy rather than maintenance strategy helps patients use corticosteroids appropriately within comprehensive treatment plans.

• Budesonide excels for acute flares Rapid onset makes it appropriate for crisis stabilization when speed matters most
• Herbal protocols suit maintenance therapy Lower side effect burden and sustained efficacy support long-term disease management
• Cost differentials compound over time Annual pharmaceutical expenses exceed herbal alternatives by 5-8x when including monitoring
• Dependency risk distinguishes approaches Corticosteroid tachyphylaxis contrasts with herbal protocols showing continued efficacy
• Integration strategies optimize outcomes Combined approaches leverage both modalities appropriately for severe presentations
• Personal history guides selection Prior treatment response and disease characteristics determine optimal starting approach
• Monitoring requirements differ dramatically Pharmaceutical protocols require ongoing testing that herbal alternatives eliminate

Herbal protocols offer particular advantages for patients prioritizing steroid-free remission and those with corticosteroid contraindications. The multi-pathway mechanism addresses inflammation while supporting mucosal healing without the metabolic stressors inherent to synthetic hormones. Patients who discover comprehensive digestive wellness solutions often find this holistic alignment with their health values compelling.

FAQ: Budesonide, Herbal Alternatives, and Crohn’s Treatment Questions

Is budesonide effective for maintaining long-term Crohn’s remission?

No clinical trials show budesonide is not effective for maintaining remission beyond 8-12 weeks. The medication achieves 42-67% remission rates during acute treatment, but relapse rates upon discontinuation exceed 50% within six months. Long-term use triggers concerning side effects including bone density loss and adrenal suppression that outweigh maintenance benefits.

Can I switch from budesonide to herbal supplements without a flare?

Yes with proper tapering protocol and physician oversight, most patients transition successfully. Allow 2-4 weeks of overlap where herbal compounds reach therapeutic levels before beginning gradual budesonide reduction. Monitor inflammatory markers weekly during transition, with typical tapers reducing dose by 3mg every two weeks.

What makes the four-herb formula different from other IBD treatments?

Multi-pathway mechanism the formula addresses inflammation through several pathways simultaneously rather than single-target suppression. Each herb contributes distinct anti-inflammatory compounds, mucosal repair promoters, and microbiome modulators working synergistically, unlike single-mechanism pharmaceuticals.

Does insurance cover herbal supplements for inflammatory bowel disease?

No herbal supplements for IBD are not covered by standard insurance plans. However, the $56 monthly cost remains significantly lower than budesonide copays plus monitoring expenses for most patients, making out-of-pocket herbal pricing financially competitive with insured pharmaceutical alternatives.

How quickly do herbal protocols work compared to budesonide?

Herbal onset takes 4-8 weeks versus 2-4 weeks for budesonide the Mediterranean diet and herbal combination protocols require patience during initial weeks. However, herbal-induced remission demonstrates greater durability, with many patients maintaining improvement months after completing protocols, unlike pharmaceutical relapse patterns.

Are there side effects from the four-herb Chinese medicine formula?

Minimal extensive patient use demonstrates no significant adverse effects across monitored populations. Unlike corticosteroids, the herbal formula shows no adrenal suppression, bone density impacts, metabolic disturbances, or dependency development, making it suitable for extended use when needed.

Can I take herbal supplements alongside my current Crohn’s medications?

Generally yes drug-herb interactions with properly formulated Chinese medicine products remain minimal. Provide complete medication lists to both prescribing physicians and supplement providers. Some patients successfully combine herbal support with reduced pharmaceutical dosing under careful medical supervision.

What percentage of patients achieve remission with herbal protocols?

Comparable rates to budesonide patient outcomes show remission rates similar to pharmaceutical alternatives, with the added benefit of sustained improvement without dependency. Individual response varies based on disease severity, adherence to protocol, and quality of supplement sourcing.

@keyframes hoox-lf-in-hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom {
from { opacity: 0; transform: translateY(8px); }
to { opacity: 1; transform: translateY(0); }
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom {
width: 100%;
max-width: 100%;
box-sizing: border-box;
display: flex;
flex-direction: column;
gap: 20px;
margin: 48px 0;
padding: 32px 28px;
border-radius: 16px;
background: #ffffff;
color: #111111;
font-family: inherit;
border: 1px solid #E2E8F0;
animation: hoox-lf-in-hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom 0.3s cubic-bezier(0.16, 1, 0.3, 1);
direction: inherit;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-form-header {
display: flex;
flex-direction: column;
gap: 8px;
text-align: center;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-form-header h2 {
margin: 0;
font-size: 1.5em;
font-weight: 700;
line-height: 1.3;
color: #111111;
border: none;
padding: 0;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-form-header p {
margin: 0;
font-size: 1em;
line-height: 1.6;
color: #64748B;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom form[data-hx-form] {
margin: 0;
display: flex;
flex-direction: column;
gap: 14px;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-field-wrap {
position: relative;
width: 100%;
box-sizing: border-box;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-field-wrap input {
width: 100%;
box-sizing: border-box;
height: 44px;
padding-inline-start: 42px;
padding-inline-end: 14px;
border: 1px solid #E2E8F0;
border-radius: 10px;
font-size: 14px;
color: #111111;
font-family: inherit;
background-color: #F8FAFC;
transition: border-color 0.15s ease, box-shadow 0.15s ease, background-color 0.15s ease;
outline: none;
direction: inherit;
text-align: start;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-field-wrap input::placeholder {
color: #94A3B8;
opacity: 1;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-field-wrap input:focus {
background-color: #FFFFFF;
border-color: #0077B6,#00B4D8,#90E0EF;
box-shadow: 0 0 0 3px rgba(15, 23, 42, 0.08);
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-field-icon {
position: absolute;
top: 0;
bottom: 0;
inset-inline-start: 0;
width: 42px;
display: flex;
align-items: center;
justify-content: center;
pointer-events: none;
color: #94A3B8;
transition: color 0.15s ease;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-field-wrap:focus-within .hoox-field-icon {
color: #0077B6,#00B4D8,#90E0EF;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom button[type=”submit”] {
width: 100%;
height: 44px;
margin-top: 4px;
border: none;
border-radius: 10px;
background: #0077B6,#00B4D8,#90E0EF;
color: #FFFFFF;
font-size: 14px;
font-weight: 600;
cursor: pointer;
transition: opacity 0.15s ease, transform 0.15s ease, box-shadow 0.15s ease;
box-shadow: 0 1px 2px 0 rgba(0, 0, 0, 0.05);
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom button[type=”submit”]:hover {
opacity: 0.94;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom button[type=”submit”]:active {
transform: scale(0.99);
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom button[type=”submit”]:disabled {
opacity: 0.6;
cursor: not-allowed;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disclaimer {
margin: 0;
text-align: center;
font-size: 12px;
line-height: 1.5;
color: #94A3B8;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disclaimer a {
color: inherit;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disclaimer a:hover {
text-decoration: none;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-success {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
position: relative;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-confetti {
position: absolute;
inset: 0;
overflow: visible;
pointer-events: none;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-confetti span {
position: absolute;
top: 50%;
left: 50%;
width: 7px;
height: 11px;
background: var(–hoox-c);
border-radius: 2px;
opacity: 0;
animation: hoox-confetti-burst 0.9s ease-out forwards;
animation-delay: var(–hoox-d, 0s);
}

@keyframes hoox-confetti-burst {
0% { opacity: 1; transform: translate(-50%, -50%) rotate(0deg) scale(1); }
100% { opacity: 0; transform: translate(calc(-50% + var(–hoox-tx)), calc(-50% + var(–hoox-ty))) rotate(var(–hoox-rz)) scale(0.5); }
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-success-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #ECFDF5;
display: flex;
align-items: center;
justify-content: center;
font-size: 26px;
line-height: 1;
animation: hoox-success-pop 0.4s cubic-bezier(0.34, 1.56, 0.64, 1);
}

@keyframes hoox-success-pop {
from { opacity: 0; transform: scale(0.5); }
to { opacity: 1; transform: scale(1); }
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-success-text {
margin: 0;
text-align: center;
font-size: 15px;
font-weight: 600;
line-height: 1.5;
color: #111111;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disabled-state {
display: none;
flex-direction: column;
align-items: center;
gap: 14px;
padding: 12px 0;
text-align: center;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disabled-icon {
width: 52px;
height: 52px;
border-radius: 50%;
background: #F1F5F9;
display: flex;
align-items: center;
justify-content: center;
color: #64748B;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disabled-text {
margin: 0;
font-size: 14px;
line-height: 1.6;
color: #64748B;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disabled-text a {
color: inherit;
font-weight: 600;
text-decoration: underline;
text-underline-offset: 2px;
}

#hoox-f-6ce66380-be7c-43d6-b2cb-0ef1d0-bottom .hoox-disabled-text a:hover {
text-decoration: none;
}